表紙
市場調査レポート

MediPoint:腫瘍向けコンパニオン診断検査−−現在・将来の市場参入企業

MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players

発行 GlobalData 商品コード 304750
出版日 ページ情報 英文 281 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
MediPoint:腫瘍向けコンパニオン診断検査−−現在・将来の市場参入企業 MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players
出版日: 2014年05月26日 ページ情報: 英文 281 Pages
概要

コンパニオン診断検査では、体外診断用の装置や画像装置を用いた、安全なやり方で治療実施手段と定義されています。体外でのコンパニオン診断検査では、特定の疾患・治療法に関連したバイオマーカーの有無・発現状況を計測します。

当レポートでは、世界の主要国(米国・フランス・ドイツ・イタリア・スペイン・英国・日本・中国・インド)における、各種腫瘍向けコンパニオン診断検査の関連市場での既存・新規参入企業について分析し、市場全体の将来展望や予想成長率、市場の促進・抑制要因、上市済み/治験中の主要製品の概要、現在・将来の競争動向、主要企業のプロファイル(事業内容、戦略、業績、SWOT分析)などを調査・考察して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 分析の背景
  • 関連調査

第3章 競合製品の評価

  • 概要
  • 現在上市済みの製品の活用方法
    • 免疫組織化学
    • 蛍光 in situ ハイブリダイゼーション
    • ポリメラーゼ連鎖反応
  • 競合製品の分析
    • 乳がんのコンパニオン診断検査
    • 大腸がんのコンパニオン診断検査
    • メラノーマのコンパニオン診断検査
    • 非小細胞肺がんのコンパニオン診断検査

第4章 パイプライン製品の評価

  • 概要
  • 開発段階別のパイプライン
  • パイプライン製品のプロファイル
    • 乳がんのコンパニオン診断検査
    • 大腸がんのコンパニオン診断検査
    • メラノーマのコンパニオン診断検査
    • 非小細胞肺がんのコンパニオン診断検査

第5章 現在・将来の市場参入企業

  • 企業戦略の傾向
    • コンパニオン診断のビジネスモデル
  • 企業プロファイル
    • コンパニオン診断検査法を開発している製薬/治療企業
    • コンパニオン診断検査法を(製薬企業と共同で)開発している診断企業

第6章 付録

図表一覧

目次
Product Code: GDME1026FPR

A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy. This report provides an analysis of the companion diagnostic market for four major cancers in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the some of the Asia-Pacific (APAC) regions (Japan, China, and India), and identifies the unmet needs in this companion diagnostics market. This report analyses companion diagnostic tests used in breast, colorectal, melanoma and non-small cell lung cancer. This report also discusses physician attitudes towards current companion diagnostic tests, and the future of companion diagnostic tests. This report focuses on the major test kits that are supplied to pathology laboratories.

The report identifies and analyzes the key companies shaping and driving the Companion Diagnostic market. The report provides insight into the competitive Companion Diagnostic landscape, including new companies entering the market and pipeline products in development. This report is built using data and information sourced from proprietary databases, secondary sources and primary research interviews and survey with leading doctors, with in-house analysis conducted by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Companion Diagnostic
  • Competitor assessment including device approval analysis.
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors using Companion Diagnostic in clinical practice.

Reasons to buy

  • Gain a high level view of the trends shaping and driving the Companion Diagnostic market.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Competitive Assessment

  • 3.1. Overview
  • 3.2. Techniques in Use by Currently Marketed Products
    • 3.2.1. Immunohistochemistry
    • 3.2.2. Fluorescence In Situ Hybridization
    • 3.2.3. Polymerase Chain Reaction
  • 3.3. Competitive Analysis
    • 3.3.1. Breast Cancer Companion Diagnostic Tests
    • 3.3.2. Colorectal Cancer Companion Diagnostic Tests
    • 3.3.3. Melanoma Companion Diagnostic Tests
    • 3.3.4. Non-Small Cell Lung Cancer Companion Diagnostic Tests

4. Pipeline Products

  • 4.1. Overview
  • 4.2. Pipeline by Phase of Development
  • 4.3. Pipeline Product Profiles
    • 4.3.1. Breast Cancer Companion Diagnostic Tests
    • 4.3.2. Colorectal Cancer Companion Diagnostic Tests
    • 4.3.3. Melanoma Companion Diagnostic Tests
    • 4.3.4. Non-Small Cell Lung Cancer Companion Diagnostic Tests

5. Current and Future Players

  • 5.1. Trends in Corporate Strategy
    • 5.1.1. Companion Diagnostics Business Models
  • 5.2. Company Profiles
    • 5.2.1. Pharmaceutical/Therapy Companies Developing Companion Diagnostic Tests
    • 5.2.2. Diagnostics Companies Developing Companion Diagnostic Tests (in Partnership with Pharmaceutical Companies)

6. Appendix

  • 6.1. Bibliography
  • 6.2. Abbreviations
  • 6.3. Report Methodology
    • 6.3.1. Coverage
    • 6.3.2. Secondary Research
    • 6.3.3. Forecasting Methodology
  • 6.4. Physicians Included in this Study
  • 6.5. About the Authors
    • 6.5.1. Andrew Thompson, Ph.D., Senior Analyst, In Vitro Diagnostics
    • 6.5.2. Derek Archila, MBA, Lead Analyst, Medical Devices
    • 6.5.3. Bonnie Bain, PhD, Global Head of Healthcare
  • 6.6. Disclaimer

List of Tables

  • Table 1: HER2 FISH/iQFISH PharmDx Product Profile
  • Table 2: Common Reasons for HER2 FISH Failure
  • Table 3: HER2 FISH PharmDx/HER2 iQFISH PharmDx SWOT Analysis
  • Table 4: HercepTest Product Profile
  • Table 5: HercepTest Scoring Algorithm
  • Table 6: HercepTest SWOT Analysis
  • Table 7: HER2 CISH PharmDx Product Profile
  • Table 8: HER2 CISH PharmDx SWOT Analysis
  • Table 9: SPOT-Light HER2 CISH Kit Product Profile
  • Table 10: SPOT-Light HER2 CISH Kit SWOT Analysis
  • Table 11: Leica Bond Oracle HER2 IHC System Product Profile
  • Table 12: Leica Bond Oracle HER2 IHC System Test Algorithm
  • Table 13: Leica Bond Oracle HER2 IHC System SWOT Analysis
  • Table 14: Biogenex INSITE HER2/Neu Product Profile
  • Table 15: Biogenex INSITE HER2/Neu SWOT Analysis
  • Table 16: Abbott Pathvysion HER-2 DNA Probe Kit Product Profile
  • Table 17: Abbott Pathvysion HER-2 DNA Probe Kit SWOT Analysis
  • Table 18: Ventana INFORM HER2 Dual ISH Assay Product Profile
  • Table 19: Ventana INFORM HER2 Dual ISH Assay SWOT Analysis
  • Table 20: Pathway HER2/Neu IHC Product Profile
  • Table 21: Pathway HER2/Neu IHC SWOT Analysis
  • Table 22: HerMark Product Profile
  • Table 23: HerMark SWOT Analysis
  • Table 24: Therascreen KRAS RGQ Product Profile
  • Table 25: Therascreen KRAS RGQ SWOT Analysis
  • Table 26: Cobas KRAS Mutation Test Product Profile
  • Table 27: Cobas KRAS Mutation Test SWOT Analysis
  • Table 28: EGFR PharmDx Kit Product Profile
  • Table 29: EGFR PharmDx Kit SWOT Analysis
  • Table 30: THxID BRAF Product Profile
  • Table 31: Effect of Melanin on the THxID BRAF PCR Test
  • Table 32: THxID BRAF SWOT Analysis
  • Table 33: Cobas 4800 BRAF V600 Mutation Test - Melanoma Product Profile
  • Table 34: Interpretation of Cobas BRAF V600 Mutation Test - Melanoma
  • Table 35: Cobas 4800 BRAF V600 Mutation Test - Melanoma SWOT Analysis
  • Table 36: Vysis ALK Break Apart FISH Probe Kit Product Profile
  • Table 37: Abbott Vysis ALK Break Apart FISH Probe Kit SWOT Analysis
  • Table 38: Amoy-Dx EML4-ALK Fusion Gene Detection Kit Product Profile
  • Table 39: Amoy-Dx EML4-ALK Fusion Gene Detection Kit SWOT Analysis
  • Table 40: Therascreen EGFR RGQ PCR Kit Product Profile
  • Table 41: Therascreen EGFR RGQ PCR Kit SWOT Analysis
  • Table 42: ALK IHC Test Product Profile
  • Table 43: ALK IHC Test SWOT Analysis
  • Table 44: Cobas EGFR Mutation Test Product Profile
  • Table 45: Cobas EGFR Mutation Test SWOT Analysis
  • Table 46: Companion Diagnostic Tests Pipeline, 2014
  • Table 47: Neuvax Companion Diagnostic Assay Product Profile
  • Table 48: Neuvax Companion Diagnostic Assay Product SWOT Analysis
  • Table 49: Companion Diagnostic Test - Palbociclib Product Profile
  • Table 50: Companion Diagnostic Test - Palbociclib SWOT Analysis
  • Table 51: Companion Diagnostic Test - Breast Cancer Product Profile
  • Table 52: Companion Diagnostic Test - Breast Cancer SWOT Analysis
  • Table 53: Onapristone Companion Diagnostic Assay Product Profile
  • Table 54: Onapristone Companion Diagnostic Assay SWOT Analysis
  • Table 55: Aromatase Inhibitor Biomarker - Companion Diagnostic Test Product Profile
  • Table 56: Aromatase Inhibitor Biomarker - Companion Diagnostic Test SWOT Analysis
  • Table 57: BRAF Companion Diagnostic Assay - Colon Cancer Product Profile
  • Table 58: BRAF Companion Diagnostic Assay - Colon Cancer SWOT Analysis
  • Table 59: KRAS Companion Diagnostic Assay - Colon Cancer Product Profile
  • Table 60: KRAS Companion Diagnostic Assay - Colon Cancer SWOT Analysis
  • Table 61: PIK3CA Companion Diagnostic Assay - Colorectal Cancer Product Profile
  • Table 62: PIK3CA Companion Diagnostic Assay - Colorectal Cancer SWOT Analysis
  • Table 63: Vectibix Companion Diagnostic Product Profile
  • Table 64: Vectibix Companion Diagnostic SWOT Analysis
  • Table 65: MAGE-A3 Companion Skin Cancer Assay Product Profile
  • Table 66: MAGE-A3 Companion Skin Cancer Assay SWOT Analysis
  • Table 67: GNAQ/GNA11 Companion Diagnostic Assays - Melanoma Product Profile
  • Table 68: GNAQ/GNA11 Companion Diagnostic Assays - Melanoma SWOT Analysis
  • Table 69: Companion Diagnostic Test - Melanoma Cancer Product Profile
  • Table 70: Companion Diagnostic Test - Melanoma Cancer SWOT Analysis
  • Table 71: KRAS Companion Diagnostic Assay - Melanoma Product Profile
  • Table 72: KRAS Companion Diagnostic Assay - Melanoma SWOT Analysis
  • Table 73: Companion Diagnostic Test - Melanoma Product Profile
  • Table 74: Companion Diagnostic Test - Melanoma SWOT Analysis
  • Table 75: BRAF Companion Diagnostic Assay - Lung Cancer Product Profile
  • Table 76: BRAF Companion Diagnostic Assay - Lung Cancer SWOT Analysis
  • Table 77: KRAS Companion Diagnostic Assay - Lung Cancer Product Profile
  • Table 78: KRAS Companion Diagnostic Assay - Lung Cancer SWOT Analysis
  • Table 79: MET Companion Diagnostic Assay - Lung Cancer Product Profile
  • Table 80: MET Companion Diagnostic Assay - Lung Cancer SWOT Analysis
  • Table 81: PIK3CA Companion Diagnostic Assay - Lung Cancer Product Profile
  • Table 82: PIK3CA Companion Diagnostic Assay - Lung Cancer SWOT Analysis
  • Table 83: Companion Diagnostic Device - Lung Cancer Product Profile
  • Table 84: Companion Diagnostic Device - Lung Cancer SWOT Analysis
  • Table 85: Companion Diagnostic Test - Crizotinib Product Profile
  • Table 86: Companion Diagnostic Test - Crizotinib SWOT Analysis
  • Table 87: Companion Diagnostic Test - Dacomitinib Product Profile
  • Table 88: Companion Diagnostic Test - Dacomitinib SWOT Analysis
  • Table 89: T790M Mutation Companion Diagnostic Test Product Profile
  • Table 90: T790M Mutation Companion Diagnostic Test SWOT Analysis
  • Table 91: Entinostat Companion Diagnostic Assay Product Profile
  • Table 92: Entinostat Companion Diagnostic Assay SWOT Analysis
  • Table 93: MUC1 Expression Companion Diagnostic Test Product Profile
  • Table 94: MUC1 Expression Companion Diagnostic Test SWOT Analysis
  • Table 95: Companion Diagnostic Assay - NSCLC Product Profile
  • Table 96: Companion Diagnostic Assay - NSCLC SWOT Analysis
  • Table 97: Company Profile - Amgen
  • Table 98: Amgen's Key Products
  • Table 99: Selected Amgen Anti-Cancer Therapies Currently in Clinical Trials
  • Table 100: Amgen SWOT Analysis
  • Table 101: Company Profile - Arno Therapeutics
  • Table 102: Selected Arno Therapeutics Anti-Cancer Therapies Currently in Clinical Trials
  • Table 103: Arno Therapeutics SWOT Analysis
  • Table 104: Company Profile - AstraZeneca
  • Table 105: Key Events in the Development of AstraZeneca's Drug Portfolio Since 2011
  • Table 106: Key Project Terminations by AstraZeneca Since 2008
  • Table 107: AstraZeneca SWOT Analysis
  • Table 108: Company Profile - Bristol-Myers Squibb
  • Table 109: Recent Key Product Approvals from Bristol-Myers Squibb
  • Table 110: Recent Key BMS Partnerships and Agreements
  • Table 111: Bristol-Myers Squibb SWOT Analysis
  • Table 112: Company Profile - Clovis Oncology
  • Table 113: Clovis Oncology's Key Products
  • Table 114: Clovis Oncology SWOT Analysis
  • Table 115: Company Profile - Eli Lilly and Company
  • Table 116: Eli Lilly and Company SWOT Analysis
  • Table 117: Company Profile - Genentech
  • Table 118: Selected Genentech Marketed Products
  • Table 119: Genentech SWOT Analysis
  • Table 120: Company Profile - Pfizer
  • Table 121: Pfizer SWOT Analysis
  • Table 122: Company Profile - Syndax Pharmaceuticals
  • Table 123: Syndax Pharmaceuticals SWOT Analysis
  • Table 124: Company Profile - Abbott Laboratories
  • Table 125: Abbott's Key Product Areas
  • Table 126: Abbott Laboratories SWOT Analysis, 2013
  • Table 127: Company Profile - Amoy Diagnostics
  • Table 128: Amoy Diagnostics SWOT Analysis, 2013
  • Table 129: Company Profile - Biogenex Laboratories
  • Table 130: Biogenex Laboratories SWOT Analysis, 2013
  • Table 131: Company Profile - BioMerieux
  • Table 132: BioMerieux SWOT Analysis, 2013
  • Table 133: Company Profile - Dako (Agilent Technologies)
  • Table 134: Dako/Agilent Technologies SWOT Analysis
  • Table 135: Company Profile - Illumina
  • Table 136: Illumina Product Areas
  • Table 137: Illumina SWOT Analysis
  • Table 138: Company Profile - Leica Biosystems (Danaher)
  • Table 139: Leica Biosystems/Danaher SWOT Analysis
  • Table 140: Company Profile - Life Technologies (Thermo Fisher Scientific)
  • Table 141: Life Technologies SWOT Analysis
  • Table 142: Company Profile - MolecularMD
  • Table 143: MolecularMD SWOT Analysis
  • Table 144: Company Profile - Myriad Genetics
  • Table 145: Myriad Genetics Major Product Areas
  • Table 146: Myriad Genetics SWOT Analysis
  • Table 147: Company Profile - Qiagen
  • Table 148: Qiagen Major Product Areas
  • Table 149: Qiagen SWOT Analysis
  • Table 150: Company Profile - Roche Diagnostics
  • Table 151: Roche SWOT Analysis
  • Table 152: Company Profile - Siemens Healthcare
  • Table 153: Siemens Healthcare SWOT Analysis
  • Table 154: Company Profile - Ventana Medical Systems
  • Table 155: Ventana Medical Systems SWOT Analysis

List of Figures

  • Figure 1: EGFR PharmDx Test Adoption Curve
  • Figure 2: Probe Arrangement in the Vysis ALK Break Apart FISH Probe Kit
  • Figure 3: Scorpion Primers
  • Figure 4: Increase in High- and Moderate-Complexity Molecular Tests
  • Figure 5: Expected Companion Diagnostic Test Pipeline, US Approvals, 2014-2019
Back to Top